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Abstract
Previous studies have demonstrated altered brain activity in Alzheimer’s disease using task
based functional MRI (fMRI), network based resting-state fMRI, and glucose metabolism
from 18F fluorodeoxyglucose-PET (FDG-PET). Our goal was to define a novel indicator of
neuronal activity based on a first-order textural feature of the resting state functional MRI
(RS-fMRI) signal. Furthermore, we examined the association between this neuronal activity
metric and glucose metabolism from 18F FDG-PET. We studied 15 normal elderly controls
(NEC) and 15 probable Alzheimer disease (AD) subjects from the AD Neuroimaging Initia-
tive. An independent component analysis was applied to the RS-fMRI, followed by template
matching to identify neuronal components (NC). A regional brain activity measurement was
constructed based on the variation of the RS-fMRI signal of these NC. The standardized glu-
cose uptake values of several brain regions relative to the cerebellum (SUVR) were mea-
sured from partial volume corrected FDG-PET images. Comparing the AD and NEC groups,
the mean brain activity metric was significantly lower in the accumbens, while the glucose
SUVR was significantly lower in the amygdala and hippocampus. The RS-fMRI brain activity
metric was positively correlated with cognitive measures and amyloid β1–42 cerebral spinal
fluid levels; however, these did not remain significant following Bonferroni correction. There
was a significant linear correlation between the brain activity metric and the glucose SUVR
measurements. This proof of concept study demonstrates that this novel and easy to imple-
ment RS-fMRI brain activity metric can differentiate a group of healthy elderly controls from
a group of people with AD.
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Introduction
Alzheimer disease is considered to be a progressive neurodegenerative condition clinically
characterized by cognitive dysfunction and memory impairments [1] that appear to result
from the pathological accumulation of amyloid plaques and neurofibrillary tangles [2, 3].
Brain atrophy measured by magnetic resonance imaging (MRI) has been established as an
important biomarker associated with disease progression and treatment response [4–6].
Another established biomarker is reduced regional uptake of 18F labeled fluorodeoxyglucose
(FDG) measured using positron emission tomography (PET) [7], indicating lower glucose
metabolism in Alzheimer’s disease [8, 9].
Neuronal activity can also be inferred from blood oxygen level dependent (BOLD) contrast
as exploited in functional MRI (fMRI). More recently, resting state fMRI (RS-fMRI) measures
of spontaneous low frequency fluctuations (< 0.1 HZ) in the BOLD signal have been used to
identify functionally connected brain regions (networks) without the performance of an overt
task [10, 11]. Previous studies [12, 13] have shown that several resting state networks can be
identified, and may be altered in Alzheimer’s disease. For example, multiple studies have
found RS-fMRI can be used to show disrupted connectivity between the hippocampus and
other brain regions in Alzheimer disease [13–15]. Furthermore, the interconnectivity of brain
regions can be used to classify subjects with Alzheimer disease, amnestic mild cognitive
impairment, and healthy elderly [16].
A number of different statistical and mathematic approaches have been used to infer func-
tional connectivity from RS-fMRI data. One common approach is to use the a-priori selection
of a seed region of interest (ROI) [17–19] to determine the correlation between the mean
BOLD signal time course within the ROI and the BOLD signal time courses of all other pixels
in the brain. However the requirement for a-priori seed selection makes it difficult to examine
the functional connectivity across the whole brain. Another popular multivariate technique for
analyzing whole brain connectivity is independent component analysis (ICA) [20–22]. This
approach does not require a-priori information and decomposes the BOLD signal into a set of
spatial and temporal components that are maximally statistically independent [23]. The ICA
method is also an efficient approach to extract scanner noise, as well as physiological and
motion artifacts from the BOLD signal [24]. One of the major challenges with the ICA tech-
nique is to determine which components represent physiologically relevant networks, and
which components represent noise. However methods now exist to differentiate neuronal
from non-neuronal components [25].
Brain regions associated with the default mode network (DMN) have been repeatedly
implicated in the pathogenesis of Alzheimer’s disease [13, 26]. FDG-PET studies have shown
reduced glucose metabolism in the medial temporal cortex, hippocampus, and posterior cin-
gulate cortex [27–29]. Decreased functional connectivity in the DMN has also been associated
with increased amyloid deposition measured using Pittsburgh compound B PET [30, 31]. In
addition, several studies in healthy controls have shown a relationship between glucose metab-
olism measured by PET and the RS-fMRI signal. For example, Di et. al. showed that metabolic
activity was correlated with independent component (IC) maps of the BOLD signal in regions
that are functionally connected [32]. Similarly, Tomasi et. al. [33] measured the amplitude of
the RS-fMRI signal and glucose metabolism by FDG-PET and demonstrated that higher
metabolism was correlated with a higher amplitude of the RS-fMRI signal in the cerebellum,
occipital, and parietal cortices. Finally, Riedl et. al. [34] found a correlation between local brain
activity in specific regions of interest measured from FDG-PET data and functional connectiv-
ity measured by RS-fMRI using seed-based methods.
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Previous RS-fMRI studies have shown a reduction in functional connectivity between struc-
tures based on the strength of the correlation in the BOLD signal [18, 35]. Here, we define a
novel metric of brain activity based on a first-order texture feature defined as the standard
deviation of the magnitude of the BOLD fluctuation. The purpose of this study was to deter-
mine whether this new metric could be used to accurately differentiate healthy elderly individ-
uals from people with mild Alzheimer disease. Our hypothesis was that the fluctuation of the
magnitude of the BOLD signal as a function of time is related to neuronal activity and there-
fore will also correlate with FDG-PET measures of glucose metabolism. Our goal was to dem-
onstrate the efficacy of a new indicator of Alzheimer’s disease based on the fluctuation of the
magnitude of the RS-fMRI signal. Furthermore, we examined the association between the fluc-
tuation magnitude of the neuronal derived RS-fMRI signal and FDG-PET.
Theory
In this study, we propose a brain activity measurement derived directly from the RS-fMRI sig-
nal. The RS-fMRI signal can be represented as an i x v matrix, where i represents each pixel,
and v represents the number of volumes acquired in the fMRI acquisition. The ICA method
decomposes the RS-fMRI signal into: 1) an i x n matrix of independent component spatial
maps, where n represents the number of components, and 2) an n x v matrix of mixing weights
(W) or IC time-courses. Here, the number (k) of legitimate ICs was identified using a good-
ness-of-fit (GoF) calculation, a multiple template matching method and a support vector
machine (SVM) classifier [25] that included only the neuronal components (NC) (Fig 1A).
The weighting function for each neuronal component, Wk(tv) is then multiplied (Hadamard
product, Eq 1, Fig 1B) with the equal length vector given by the RS-fMRI time series for each
pixel, Si(tv), generating a new vector of equal length BSAi,k(tv):
BSAi;kðtvÞ ¼ SiðtvÞ  WkðtvÞ ð1Þ
where BSAi,k represents the BOLD signal amplitude (BSA) for each neuronal component k in
pixel i. Then, the standard deviation (SD) is calculated for BSAi,k and is multiplied with the
neuronal component (NCi,k) (Fig 1C). The sum of this metric (Eq 2, Fig 1D) for all neuronal
components in a pixel represents the neuronal activity and is used to produce a neuronal activ-
ity map.
Neuronal Activityi ¼
Xk
j¼1
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SDðBSAi;jðtvÞÞ  NCi;j
q
ð2Þ
Materials and methods
Study subjects
Data used in the preparation of this article (S1 and S2 Tables) were obtained from the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 as a public-private partnership, led by Principal Investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance
imaging, positron emission tomography, other biological markers, and clinical and neuro-
psychological assessment can be combined to measure the progression of mild cognitive
impairment and early Alzheimer’s disease. Written informed consent for participation in the
study was obtained from each participant, or their family. Data acquisition was approved by
the local ethics review board at each participating site.
Low frequency BOLD signal variations are decreased in Alzheimer disease
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To test the algorithm, this study included data from 15 normal elderly controls (NEC) and
15 subjects with probable Alzheimer disease of mild severity obtained from the ADNI data-
base. We included participants that had 3.0 Tesla T1-weighted anatomical scans and 10-minute
RS-fMRI data acquisitions. A subset of this group (13 NEC, and 11 subjects with mild Alzhei-
mer disease) also had an FDG-PET scan available. Structural T1-weighted images were
obtained using a sagittal 3D magnetization-prepared rapid acquisition with a gradient echo
MP-RAGE sequence with pixel size 1mm×1mm×1.2mm; flip angle ~9˚; TE ~4 ms; TR ~7 ms;
matrix, 256x256; 170 slices [36]. The RS-fMRI scans were acquired using a single shot echo
planer imaging (EPI) pulse sequence with pixel size 3.3mm×3.3mm×3.3mm; flip angle 80.0˚;
TE 30 ms; TR ~3000 ms; matrix = 64x64; 48 slices [37]. FDG-PET images were acquired using
similar protocols on all PET scanners but varied somewhat in resolution, spacing, and dimen-
sion. However images were normalized and motion corrected [38] prior to analysis. The
FDG-PET scans consisted of six-5 minute frames acquired starting 30 minutes after FDG
injection [38]. All frames were registered to the first frame and then averaged to produce a sin-
gle static image. All subjects were also evaluated with the mini mental state examination
(MMSE) [39] to assess cognition. In addition, CSF biomarkers including total Tau protein
(Tau), phosphorylated Tau protein (P-Tau) and amyloid-β (Aβ1–42) were obtained for all sub-
jects (https://ida.loni.usc.edu/).
Fig 1. Schematic diagram of the brain activity metric calculated from the RS-fMRI signal in one pixel. The signal shown is a graphical
representation of the vector data. (A) Neuronal time courses (W) are defined by the ICA and verified using a goodness of fit calculation, multiple template
matching method and a support vector machine classifier. (B) The Hadamard product of each neuronal time course is taken with the RS-fMRI signal. (C)
The standard deviation of the resulting signal is multiplied by the neuronal component. (D) The square root of the contribution of each neuronal time course
is added to create a measure of neuronal activity.
https://doi.org/10.1371/journal.pone.0178529.g001
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RS-fMRI analysis
The brain was extracted from the RS-fMRI data and the anatomical T1-weighted images using
the brain extraction tool (BET) in the FSL software (functional MRI of the brain (FMRIB) Soft-
ware Library, Department of Clinical Neurosciences, University of Oxford, UK, http://fsl.
fmrib.ox.ac.uk/fsl/fslwiki/FSL). The brain extracted fMRI data were preprocessed, aligned and
co-registered to the MNI-152 space using the fMRI expert analysis tool (FEAT) in FSL. An ini-
tial smoothing (full-width half-maximum of 6 mm), and band-pass temporal filtering (0.01 Hz
—0.1 Hz) were applied before ICA decomposition. The ICA method (30 components) was
performed using the group ICA of the fMRI toolbox (GIFT) [40]. The ICA was followed by a
previously described three-step process [25] to identify neuronal components in each RS-
fMRI data set, all implemented in-house by Demertzi and et. al. [25]. First, a goodness of fit
(GoF) calculation was used to measure the similarity value between a component and estab-
lished resting state networks [25]. Second, the multiple templates matching method was
applied. Then, a template had to be assigned to one of the 30 components [25]. Thirdly, a sup-
port vector machine was used to label each component as neuronal, non-neuronal, or unde-
fined [25].
Following identification of the neuronal components, a brain activity map was constructed
from these components as described in the Theory section and co-registered to the MNI-152
standard image using linear and non-linear registration methods. Co-registration of the brain
activity map to the anatomical image was conducted using Statistical Parametric Mapping
(SPM8, Wellcome Department of Neurology, London, UK; www.fil.ion.ucl.ac.uk/spm). ROIs
were defined in the MNI-152 image using the structural segmentation method called FMRIB’s
integrated registration and segmentation tool (FIRST) in FSL because it is easily accessible to
the research community and automated. Finally, the mean intensity from each ROI in the
brain activity map was measured. A schematic representation of the steps involved in making
the brain activity measurements is provided in Fig 2.
Fig 2. Brain activity from RS-fMRI. Schematic diagram of the brain activity (BOLD signal amplitude)
measurement in different brain regions. (A) Steps involved in calculating the brain activity maps from the RS-
fMRI. (B) Regions of interest extracted from MNI-152 space. (C) Activity maps within each region of interest
from one subject.
https://doi.org/10.1371/journal.pone.0178529.g002
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PLOS ONE | https://doi.org/10.1371/journal.pone.0178529 June 5, 2017 5 / 18
Volumetric analysis
The FSL software was used to measure the volumes of the accumbens, amygdala, hippocam-
pus, caudate nucleus, thalamus, pallidum, putamen, and whole brain from the T1-weighted
image of each subject using a method similar to that previously described [41]. The volumes
were normalized to the whole brain volume in each subject.
FDG-PET analysis
The brain was also extracted from the FDG-PET images using the BET tool in FSL. A partial
volume correction method was applied to each data set using the partial volume correction
structural functional synergistic resolution recovery (PVC_SFSRR) software [42]. This soft-
ware performs pre-processing steps including co-registration of the FDG-PET with the struc-
tural image, segmentation and smoothing (8 mm), and finally partial volume correction. The
corrected FDG-PET image was co-registered to the MNI-152 template. The predefined ROIs
in the MNI-152 image were applied to the co-registered FDG-PET image. The standardized
uptake value (SUV) of each ROI was then normalized to the mean SUV of the cerebellum to
obtain the SUV ratio (SUVR) as this has been previously shown [43] to be unchanged in
healthy subjects and at the early stages of Alzheimer disease.
Statistical analysis
Prism GraphPad (Prism, version 6.00; GraphPad Software, San Diego, CA) and Matlab
toolbox (version R2010a) were used for the statistical analyses. One-way ANOVA was used to
compare brain activity between the NEC and Alzheimer disease groups (p< 0.05 considered
significant). If a significant group effect was observed, the p-values associated with follow-up
group comparisons between brain regions were Bonferroni corrected for multiple compari-
sons. The association between the brain activity measured from the RS-fMRI, MMSE score,
and CSF biomarkers were evaluated using linear regression. The significance of these associa-
tions was Bonferroni corrected for multiple comparisons. The Pearson correlation coefficient
was used to measure the association between the brain activity in gray matter obtained from
RS-fMRI and the glucose uptake from FDG-PET (p< 0.05 considered significant).
Classification model
To determine if the RS-fMRI derived brain activity measurement was a suitable biomarker
to differentiate patients with mild Alzheimer disease and healthy elderly controls, a SVM
classifier was used. Specifically, a linear SVM [44] was trained and tested on the feature
space. Regions of interest were selected based on the observed differences between groups
for either the brain activity metric or FDG-PET measured glucose metabolism. A leave-one-
out-test was used as a cross-validation to predict the label for each test subject (not involved
in the training phase). The accuracy, sensitivity, and specificity were determined after each
subject was assessed as the test subject. In the first analysis, RS-fMRI brain activity in the hip-
pocampus and accumbens, FDG-PET in the hippocampus, and hippocampal volume were
evaluated separately. In a second analysis, FDG-PET and RS-fMRI modalities were evaluated
independently incorporating data from both the hippocampus and amygdala. In a third anal-
ysis, we combined the volumetric and RS-fMRI information from the hippocampus and
accumbens.
Low frequency BOLD signal variations are decreased in Alzheimer disease
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Results
Brain maps of neuronal activity and glucose metabolism
Demographic characteristics are provided in Table 1 for all 30 subjects (S1 and S2 Tables).
There was no difference between group mean ages (healthy elderly subjects age range: 65–80
years; subjects with Alzheimer disease age range: 63–79 years), however as expected, there was a
significant difference in the MMSE score (p< 0.0001, two-tailed t-test) between the two groups.
Montreal neurological institute-152 (MNI-152) template T1-weighted images (Fig 3A and 3B)
Table 1. Demographic information for study participants.
RS-fMRI NEC RS-fMRI Alzheimer disease FDG-PET NEC FDG-PET Alzheimer disease
Number of subject (N) 15 15 13 11
Age (years) (Mean±SD) 73.5 ± 6.2 73.3 ±8.0 74.4 ± 6.1 70.9 ± 7.2
MMSE (Mean±SD) 28.9 ± 1.2 21.6 ± 2.1* 29.0 ± 1.1 21.8± 2.3*
Sex (F) 10 10 9 7
Tau (pg/ml) (Mean±SEM) 66.3± 9.8 164.5±22.8** 63.8±9.6 182.5±28.2**
P-Tau (pg/ml) (Mean±SEM) 38.9 ± 10.0 62.0±7.7 40.7±11.1 68.1±9.5
Aβ1–42 (pg/ml) (Mean±SEM) 192.5± 16.1 132.3±5.4** 179.0±15.0 131.2±7.3**
* p< 0.05 (two-tailed) and
** adjusted p value (Bonferroni) between NEC and Alzheimer disease within a single imaging modality
F = female; SEM = standard error of mean, SD = standard deviation, NEC = normal elderly controls, FDG-PET = 18fludeoxyglucose-PET, RS-fMRI = resting
state functional MRI, MMSE = mini mental state examination, P-Tau = phospho-Tau, Aβ1–42 = amyloid beta1-42.
https://doi.org/10.1371/journal.pone.0178529.t001
Fig 3. Brain activity and glucose metabolism maps. MNI-152 T1-weighted anatomical images in coronal,
sagittal, and axial orientations (A, B). Corresponding FDG-PET SUVR images of glucose metabolism from a
healthy elderly subject, and healthy elderly group averaged (C, G); a patient with Alzheimer disease, and
Alzheimer disease group averaged (D, H). Brain activity maps obtained using RS-fMRI in the same healthy
elderly subject, and healthy elderly group averaged (E, I) and patient with Alzheimer disease, and Alzheimer
disease group averaged (F, J).
https://doi.org/10.1371/journal.pone.0178529.g003
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in coronal, sagittal, and axial planes are shown with corresponding standardized uptake value
ratio (SUVR) glucose metabolism maps from the FDG-PET scan in one healthy elderly subject
(Fig 3C) and the healthy elderly group average (Fig 3G); as well as one subject with Alzheimer
disease (Fig 3D) and the Alzheimer disease group average (Fig 3H). Corresponding brain activ-
ity maps measured from the RS-fMRI in the same subjects (Fig 3E and 3F) and group averages
(Fig 3I and 3J) are also provided. There is a visible decrease in signal in the subject with Alzhei-
mer disease throughout the brain measured by both modalities.
Comparison of regional brain activity and glucose metabolism
The average brain activity measured from RS-fMRI (Fig 4) is shown for the cerebellum, amyg-
dala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen regions for the
NEC and Alzheimer disease groups. Similarly, the average relative rate of glucose metabolism
(Fig 5) is provided for the same regions measured by FDG-PET for the NEC and Alzheimer
disease groups. A one-way ANOVA indicated that there was a significant difference between
the two groups in RS-fMRI brain activity (p<0.0001) and FDG-PET measured glucose metab-
olism (p<0.0001). In follow-up comparisons, the difference in brain activity measured by
RS-fMRI in both sides of the accumbens (adjusted p = 0.04) and differences in relative glucose
metabolism measured using FDG-PET in the amygdala (adjusted p = 0.02), and hippocampus
(adjusted p = 0.006) remained significant following Bonferroni correction. A one-way
ANOVA indicated that there was also a significant difference between these groups in the Tau,
P-Tau and Aβ1–42 cerebral spinal fluid (CSF) levels (p<0.0001). Follow-up comparisons
showed that there were significant differences in both Tau (adjusted p<0.0001), and Aβ1–42
(adjusted p = 0.006) following Bonferroni correction for multiple comparisons. As expected, a
one-way ANOVA also showed a significant difference in normalized brain volumes between
the NEC and Alzheimer disease groups (p<0.0001). Follow-up comparisons showed
Fig 4. Regional brain activity. The average brain activity measured by RS-fMRI in NEC and Alzheimer disease
subjects in the cerebellum, amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen. The error
bars represent the standard error of the mean and asterisks show significant differences between groups (adjusted p
value, Bonferroni).
https://doi.org/10.1371/journal.pone.0178529.g004
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significant differences in normalized volume measured using MRI in the hippocampus
(p = 0.01) between the two groups.
Association between neuronal activity and glucose metabolism
A voxel by voxel correlation between gray matter RS-fMRI brain activity and the rate of glu-
cose metabolism from the FDG-PET is shown in Fig 6 for one NEC (r = 0.81, p<0.0001) and
Fig 5. Regional glucose metabolism. The average glucose metabolism measured by FDG-PET SUVR in NEC
and Alzheimer disease subjects in the amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and
putamen. The error bars represent the standard error of the mean and asterisks show significant differences
between groups (adjusted p value, Bonferroni).
https://doi.org/10.1371/journal.pone.0178529.g005
Fig 6. Relationship between glucose metabolism using FDG-PET and brain activity measured by RS-fMRI. Voxel by Voxel correlation of pixel
intensity in gray matter (r = 0.81, p< 0.001) from a healthy elderly subject (A) and a patient with Alzheimer disease (B) (r = 0.77, p< 0.001) between brain
activity using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR.
https://doi.org/10.1371/journal.pone.0178529.g006
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subject with Alzheimer disease (r = 0.77, p<0.0001). Correlations were similar in all subjects
(S1 and S2 Figs). The average r-value ± SD associated with the correlation between gray
matter activity measured using RS-fMRI and the rate of glucose metabolism measured using
FDG-PET was 0.77 ± 0.04 for the NEC group and 0.73 ± 0.03 for the Alzheimer disease group.
The average y-intercept ± SD for the NEC group was 0.23 ± 0.03 and for the Alzheimer disease
group was 0.23 ± 0.03.
Comparison of neuronal components in NEC and Alzheimer disease
The average ± SD of the number of neuronal components was 6.4 ± 1.5 for the NEC group and
5.0 ± 1.2 for the Alzheimer disease group. Unpaired t-test (two-tailed) showed significantly
fewer neuronal components in the Alzheimer disease group compared to the NEC group
(p = 0.007). Pooling all subjects, the average number of neuronal components was positively
correlated with MMSE score (r = 0.30, p = 0.002) (S3 Fig). The average ± SD of the RS-fMRI
neuronal activity (Eq 2) summed across all neuronal components in whole brain was 54.8 ±
18.3 in the NEC group and 40.6 ± 10.4 in the Alzheimer disease group. Unpaired t-test (two-
tailed) showed significantly lower neuronal activity in the Alzheimer disease group compared
to the NEC group (p = 0.01) (S4 Fig).
Association between neuronal activity and cognitive function
The relationship between RS-fMRI brain activity and clinical cognitive measurement is shown
for several brain regions in Fig 7 when pooling all groups. However, the correlations between
Fig 7. Relationship between mean brain activities measured using RS-fMRI and cognition function.
The 95% confidence intervals for the regressions are shown as dotted lines. Association between MMSE
score and brain activity in cerebellum (r = 0.50, p = 0.007, A), amygdala (r = 0.47, p = 0.009, B), thalamus
(r = 0.42, p = 0.02, C), accumbens (r = 0.48, p = 0.008, D), caudate (r = 0.41, p = 0.02, E), pallidum (r = 0.44,
p = 0.01, F), hippocampus (r = 0.44, p = 0.01, G), and putamen (r = 0.41, p = 0.02, H). These correlations were
not significant following Bonferroni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0178529.g007
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the MMSE score and brain activity in the cerebellum (r = 0.50, p = 0.007), amygdala (r = 0.47,
p = 0.009), thalamus (r = 0.42, p = 0.02), accumbens (r = 0.48, p = 0.008), caudate (r = 0.41,
p = 0.02), pallidum (r = 0.44, p = 0.01), hippocampus (r = 0.44, p = 0.01), and putamen
(r = 0.41, p = 0.02) were not significant following Bonferroni correction.
Association between neuronal activity and amyloid beta1-42
The relationship between RS-fMRI brain activity and Aβ1–42 CSF level is shown for several
brain regions in Fig 8 for all subjects. However, the correlations between the RS-fMRI brain
activity and Aβ1–42 in the cerebellum (r = 0.40, p = 0.03), amygdala (r = 0.51, p = 0.004),
accumbens (r = 0.37, p = 0.04), pallidum (r = 0.41, p = 0.02), and putamen (r = 0.41, p = 0.02)
were not significant following Bonferroni correction.
Comparison of classification accuracy
The classification accuracy of subjects using brain activity measured by RS-fMRI and relative
glucose metabolism rate measured using FDG-PET is provided in Table 2. The greatest classi-
fication accuracy, sensitivity, and specificity were obtained when using FDG-PET measure-
ment from the hippocampus. The classification model that used glucose metabolism in the
hippocampus measured by FDG-PET achieved 85% average accuracy, 84% sensitivity and
85% specificity (Table 2). The models that used brain activity in the hippocampus or accum-
bens resulted in a lower accuracy, sensitivity, and specificity (Table 2). However, the model
that combined normalized hippocampal volume and neuronal activity of RS-fMRI from the
hippocampus achieved 80% average accuracy, 72% sensitivity and 89% specificity, providing a
similar accuracy and specificity to that observed with FDG-PET glucose metabolism in the
hippocampus.
Fig 8. Relationship between mean brain activity measured using RS-fMRI and CSF derived Amyloid Beta1-42.
The 95% confidence intervals for the regressions are shown as dotted lines. Association between the brain activity and
Aβ1–42 in the cerebellum (r = 0.40, p = 0.03, A), amygdala (r = 0.51, p = 0.004, B), accumbens (r = 0.37, p = 0.04, C),
pallidum (r = 0.41, p = 0.02, D), and putamen (r = 0.41, p = 0.02, E). These correlations were not significant following
Bonferroni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0178529.g008
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Discussion
In this study we define a new metric related to neuronal activity based on the square root of
the temporal standard deviation of the RS-fMRI signal summed across all neuronal components
within a pixel. As a proof of principle, this new RS-fMRI based metric was used to compare
brain activity in normal elderly subjects and patients with mild Alzheimer disease. The brain
activity measurement is dependent on both the number of neuronal components and the tem-
poral fluctuation associated with each component. Overall lower brain activity was observed in
the mild Alzheimer disease group, particularly within the accumbens. A similar comparison in
the same subjects using FDG-PET also showed overall group differences indicating lower glu-
cose metabolism in the amygdala, and hippocampus. In a pixel-by-pixel analysis, brain activity
derived from RS-fMRI was found to be strongly correlated with glucose metabolism measured
by FDG-PET in gray matter.
The FDG-PET results from the current study are consistent with previous FDG-PET stud-
ies that have shown reduced glucose metabolism in subjects with Alzheimer disease [28, 45].
Reduced glucose metabolism has also been observed in the posterior cingulate, temporal, pari-
etal lobes and later the frontal lobe [28, 46]. Mosconi et. al. [47] showed that glucose metabo-
lism in the hippocampus and the entorhinal cortex is also reduced in the preclinical stage of
Alzheimer disease. In addition, Jagust et. al. [48] has demonstrated that medial temporal and
parietal glucose metabolism predicts cognitive decline. Glucose consumption measured by
FDG-PET is also linearly associated with neuronal activity [49]. Therefore glucose consump-
tion is considered an important indicator of presymptomatic Alzheimer disease [50].
A few RS-fMRI studies have also examined functional network activity in healthy subjects
compared to people with Alzheimer disease. Seed based analyses [17, 18] have shown
decreased functional connectivity (FC) in the medial temporal cortex, prefrontal cortex, precu-
neus, posterior cingulate, hippocampus, and thalamus in people with Alzheimer disease. Simi-
lar studies using ICA methods demonstrated reduced FC in precuneus, posterior cingulate,
Table 2. Classification results for RS-fMRI brain activity, glucose metabolism measured by FDG-PET SUVR, and normalized volume measured
using MRI. The 95% confidence interval (CI) is provided in parentheses.
SVM_linear (leave-one-out-test) Accuracy Sensitivity Specificity
RS-fMRI (Hippocampus) 0.75 0.70 0.78
(0.68–0.75) (0.70–0.82)
RS-fMRI (Accumbens) 0.56 0.42 0.68
(0.42–0.57) (0.58–0.70)
RS-fMRI (Hippocampus, and Amygdala) 0.65 0.57 0.71
(0.40–0.60) (0.69–0.80)
FDG-PET (Hippocampus) 0.85 0.84 0.85
(0.77–0.85) (0.75–0.85)
FDG-PET (Hippocampus, and Amygdala) 0.76 0.84 0.68
(0.78–0.84) (0.62–0.75)
MRI (Hippocampus) 0.67 0.64 0.70
(0.60–0.68) (0.68–0.74)
RS-fMRI (Accumbens) + MRI (Hippocampus) 0.70 0.63 0.73
(0.60–0.75) (0.73–0.80)
RS-fMRI (Hippocampus) + MRI (Hippocampus) 0.80 0.72 0.89
(0.65–0.76) (0.83–0.90)
SVM = support vector machine, FDG-PET = 18fludeoxyglucose-PET, RS-fMRI = resting state functional MRI.
https://doi.org/10.1371/journal.pone.0178529.t002
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and parietal lobe in people with amnestic mild cognitive impairment (aMCI) [51] while Zhou
et. al. [52] showed decreased FC in the default mode network including the hippocampus and
the medial temporal lobe in people with Alzheimer disease. In the current study we did not
examine functional connectivity, but instead used the RS-fMRI neuronal signal fluctuation to
define a new indicator of brain activity. When examining activity in specific brain regions, the
newly defined measurement of neuronal activity showed trends toward correlation with the
MMSE score and Aβ1–42, but these associations did not remain significant following Bonfer-
roni correction.
The new RS-fMRI metric related to brain activity showed regional differences between
NEC and Alzheimer disease subjects that were different than those observed with FDG-PET.
Previous studies have found that cerebral blood flow is closely coupled with brain metabolism
[53, 54], and that both are decreased in people with Alzheimer’s disease [55–59]. Previous
studies have also shown that there is an association between the resting brain activity and rest-
ing brain metabolism [60]. The strong correlation observed between RS-fMRI measured gray
matter activity and FDG-PET measured glucose consumption in the current study is consis-
tent with the notion that glucose metabolism is tightly coupled to the RS-fMRI measured brain
activity. This result is also consistent with a recent study by Aiello et. al. [61] who showed a
voxel-wise relationship between functional connectivity maps from RS-fMRI and glucose
uptake measured by simultaneous FDG-PET in healthy subjects. Another recent study by
Nugent et. al. [62] demonstrated that the correlation between functional connectivity maps
derived from RS-fMRI and glucose metabolism measured by FDG-PET was lower in temporal
lobe epilepsy patients compared to control subjects.
The group differentiation accuracy achieved using the brain activity metric in the accum-
bens measured by RS-fMRI was lower than that found when using FDG-PET measured glu-
cose metabolism in the hippocampus (0.85). However, when combining hippocampal volume
with brain activity from RS-fMRI in the hippocampus, the classification accuracy increased to
0.80, which is comparable to the FDG-PET results and significantly greater than using hippo-
campal volume alone. The specificity achieved when using the combined MRI-based measure-
ments (0.89) was also greater than that achieved by FDG-PET and hippocampal volume alone.
These results suggest that the combination of these MRI-based features could help to discrimi-
nate between a group of healthy elderly subjects and people with AD.
This proof of concept study demonstrates that decreased resting-state brain activity is asso-
ciated with decreased brain glucose metabolism in mild Alzheimer disease. Furthermore, we
demonstrated group classification based on a first-order textural feature (standard deviation)
of the RS-fMRI neuronal signal. There are several limitations of the current study that should
be considered. First, the sample size was limited by the availability of subjects with both ten-
minute RS-fMRI data and FDG-PET. Regardless, the new metric was still able to differentiate
between NEC and mild Alzheimer disease groups. Another limitation of this study is that we
did not perform gray atrophy correction for either the RS-fMRI or FDG-PET signal changes.
Therefore gray matter volume reduction in the hippocampus may partly explain the reduced
RS-fMRI and FDG-PET measured brain activity. However, Mosconi et. al. [63] showed
FDG-PET measured hypometabolism in the hippocampus despite atrophy correction in hip-
pocampus. Gray matter atrophy measurements in the current study did show significant dif-
ferences in the hippocampus between the two groups. However a classification model that
included both the hippocampal volume and RS-fMRI brain activity showed an improved result
to classification using either metric alone. Therefore, including this straightforward measure-
ment of neuronal activity by RS-fMRI with existing markers of neurodegeneration may
increase the reliability of detecting Alzheimer’s disease. Future studies will evaluate the
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potential to identify people with mild cognitive impairment that progress to AD and whether
this metric shows improvement following treatment.
Supporting information
S1 Fig. The association between RS-fMRI and FDG-PET SUVR in the healthy elderly
group. The scatter plots represent the voxel by voxel correlation of pixel intensity in the gray
matter of healthy elderly subjects between brain activity using RS-fMRI and corrected glucose
metabolism using FDG-PET SUVR. Each graph represents the results from a different individ-
ual.
(TIF)
S2 Fig. The association between RS-fMRI and FDG-PET SUVR in the Alzheimer disease
group. The scatter plots represent the voxel by voxel correlation of pixel intensity in the gray
matter of Alzheimer disease subjects between brain activity using RS-fMRI and corrected glu-
cose metabolism using FDG-PET SUVR. Each graph represents the results from a different
individual.
(TIF)
S3 Fig. The relationship between the number of neuronal components and cognition func-
tion measured by the MMSE score. The 95% confidence intervals for the regressions are
shown as dotted lines. A significant correlation was found between MMSE score and the num-
ber of neuronal components (r = 0.30, p = 0.002).
(TIF)
S4 Fig. Component specific brain activity maps in one healthy elderly subject and one sub-
ject with Alzheimer disease. Each image represents the square root of the standard deviation
of the magnitude of the BOLD signal fluctuation. In this example, data from each identified
neuronal component is provided in a different row. Eight neuronal components were identi-
fied in the healthy subject while only six neuronal components were identified in the subject
with AD.
(TIF)
S1 Table. Healthy elderly control subjects.
(DOCX)
S2 Table. People with Alzheimer’s disease.
(DOCX)
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